ADDED
As of October 31, 2025, 285,418,551 shares of the registrant s common stock were outstanding.
Risk Factors 14 Information About Our Executive Officers 29 Item 1B.
Business Segments As of September 30, 2025, BD s operations consisted of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional.
As further discussed in Note 8 to the consolidated financial statements contained in Item 8.
BD s new organizational structure is based upon the following five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences, which remains a critical part of BD until the separation and combination of our Biosciences and Diagnostic Solutions business with Waters Corporation ( Waters ), as further discussed below, is completed.
Advanced Patient Monitoring Advanced hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings, including noninvasive tissue oximetry systems; hemodynamic and tissue oximetry monitoring systems; pulmonary artery catheters and arterial pressure monitoring products and blood pressure measurement systems.
Specimen Management Blood collection systems including safety-engineered wingsets, needles and blood collection tubes, arterial blood gas devices, urine collection kits, molecular research tubes, capillary collection technologies alongside associated products for patient identification,data capture, storage and transportation.
BD Interventional BD Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted.
Divestitures Proposed Combination of Biosciences and Diagnostic Solutions Business with Waters Corporation On July 13, 2025, BD entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation ( Waters ) in a Reverse Morris Trust ( RMT ) transaction.
When the RMT transaction is complete, BD s Biosciences and Diagnostic Solutions businesses will be spun-off to BD shareholders and simultaneously merged with a wholly owned subsidiary of Waters.
REMOVED
As of October 31, 2024, 289,122,120 shares of the registrant s common stock were outstanding.
Risk Factors 13 Information About Our Executive Officers 27 Item 1B.
Business Segments BD s operations consist of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional.
As is further described below, on September 3, 2024, BD completed its acquisition of Edwards Lifesciences Critical Care product group ( Critical Care ), which was renamed as BD Advanced Patient Monitoring ( Advanced Patient Monitoring ) and operates as a separate organizational unit within the Company s Medical segment.
Information with respect to BD s business segments is included in Notes 8, 11 and 16, respectively, to the consolidated financial statements contained in Item 8.
Advanced Patient Monitoring Advanced hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings.
Acquisitions Edwards Lifesciences Critical Care Product Group On September 3, 2024, BD completed the acquisition of Critical Care, which was renamed as BD Advanced Patient Monitoring.
Parata On July 18, 2022, BD completed the acquisition of Parata Systems ( Parata ), an innovative provider of pharmacy automation solutions.
Since the acquisition date, financial results for Parata's product offerings are being reported within results for the Medical segment s Medication Management Solutions unit.
International Operations BD s products are manufactured and sold worldwide.